Methylthioadenosine phosphorylase (MTAP) is an enzyme ubiquitously expressed in all tissues. MTAP homozygous deletion occurs in 10-15% of different cancers such as leukemia, lymphoma, lung, brain, breast and others.
17-β-hydroxysteroid dehydrogenase type 10 (17-β-HSD10) catalyzes the turnover of steroids and neurosteroids, among other substrates, and is also a structural component of RNase P. 17-β-HSD10 is involved in the development of several pathologies, and considered a potential drug target for Alzheimer’s disease and some hormone-dependent cancers. A few 17-β-HSD10 inhibitors with either pyrazole, steroids, or benzothiazolylurea structure have been previously developed.
Methyltransferase-like 3 (METTL3) regulates mRNA translation and contributes to the most frequent modification to mRNA, the situation of a methyl group on the N6-position of A (m6A) during transcription.
The vitamin D receptor (VDR) is a member of the nuclear receptor superfamily and a potential target for treating hepatic fibrosis. Several VDR agonists, classified as “secosteroidal” and “non-secosteroidal,” have been developed.
3Z ehf and Biotx.ai AG have established a strategic partnership to help advance the development of drugs for attention deficit hyperactivity disorder (ADHD).
Boston Immune Technologies and Therapeutics Inc. (BITT) has received IND clearance from the FDA for a first-in-human trial of BITT-2101, a monoclonal antibody that targets tumor necrosis factor receptor 2 (TNFR2), in patients with relapsed or refractory non-Hodgkin lymphomas (NHLs).
The vast variety of tumors makes each cancer a world. For researchers, understanding the commonalities and divergences in their molecular underpinnings could help find successful treatments. Scientists from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) have addressed these similarities and differences in 10 different types of cancer with two proteogenomic studies to unravel the genes that lead to cancer and the galaxy of interactions that regulate them.
Aurigene Oncology Ltd. has described substituted bicyclic heterocycles acting as mucosa associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, ulcerative colitis, asthma, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), psoriasis and systemic lupus erythematosus (SLE), among others.
China Pharmaceutical University has divulged pyridoimidazole compounds acting as NLRP3 inflammasome and IL-1β (IL1B; IL-1β) inhibitors reported to be useful for the treatment of atherosclerosis, diabetes, neurodegeneration, gout, rheumatoid arthritis, chronic kidney, inflammatory bowel, and non-alcoholic fatty liver disease (NAFLD), among others.
Maze Therapeutics Inc. has identified apolipoprotein L1 (APOL1) inhibitors reported to be useful for the treatment of chronic kidney disease, focal segmental glomerulosclerosis, diabetic, hypertensive, HIV-associated nephropathy, lupus nephritis, pre-eclampsia and sepsis.
RSS
